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Prevention of Venous Thromboembolism
with Fondaparinux
 
To the Editor: 
 





fondaparinux was more effective than enoxaparin and equal-
ly safe in preventing venous thromboembolism after hip-
fracture surgery. In their study, the first dose of enoxaparin
was to be administered 12±2 hours preoperatively and the
second dose 12 to 24 hours postoperatively, according to
the recommendation of the manufacturer. However, enox-
aparin was first given postoperatively in as many as 74.4
percent of the patients in the enoxaparin group. The delay
in the initiation of enoxaparin may have resulted in an un-
derestimation of its preventive effects against thromboem-
bolism and its hemorrhagic risks, thus obscuring the relative
effects of fondaparinux. Since significant unrecognized bias
may exist, the results must be interpreted with caution. A
better explanation of why the treatment of the majority of
the patients did not conform to the study protocol would
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Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fondaparinux com-
pared with enoxaparin for the prevention of venous thromboembolism af-
ter hip-fracture surgery. N Engl J Med 2001;345:1298-304.
 
To the Editor: 
 
Several methodologic issues have to be
considered in interpreting the results reported by Eriksson
et al. Other investigators have found that the initiation of
antithrombotic prophylaxis close to the time of surgery is
more effective than delaying prophylaxis and that the effi-




 It is therefore
apparent that the superiority of the pentasaccharide report-
ed by Eriksson et al. reflects the timing of the initiation of
treatment in the early postoperative period, the doubling of
the dose within 24 hours after surgery, and the administra-
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Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the 
prevention of deep-vein thrombosis after total hip replacement. N Engl J 
Med 2001;344:619-25.
 
To the Editor: 
 





low-molecular-weight heparins need to be administered pre-
operatively to provide maximal benefit. The timing of the
commencement of treatment with heparin and low-molec-
ular-weight heparins has been long debated; a recent study





of a difference weakens the editorialist’s suggestion that
fondaparinux “may find its initial niche in patients under-
going regional anesthesia” because of the fact that it can be
commenced postoperatively. The pharmacologic profile of
fondaparinux does not make it more suitable than other
agents to use in combination with regional anesthesia. On
the contrary, it is long acting and its effects are difficult to
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monitor or reverse, so that the precautions required when
spinal or epidural anesthesia is combined with periopera-
tive fondaparinux would need to be as stringent as those for
low-molecular-weight heparins, if not more so. At present,
there appears to be no reason to commence fondaparinux
therapy any earlier or later after surgery than treatment with
any of the low-molecular-weight heparins is begun, and in
my opinion, a fair comparison of the efficacy of these agents






















Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin 
prophylaxis using dalteparin extended out-of-hospital vs in-hospital war-
farin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, 
randomized comparison. Arch Intern Med 2000;160:2208-15.
 
To the Editor: 
 
After reading Dr. Diuguid’s editorial, I still
have a question concerning the choice of low-molecular-
weight heparins for the treatment of venous thromboembo-
lism. Is it permissible to recommend dalteparin instead of
enoxaparin for the treatment of venous thromboembolism,
especially if there are major differences in cost? Are we tak-
ing a leap of faith to use these low-molecular-weight hepa-
















To the Editor: 
 
Drs. Murashige and Kami and Dr. Marlov-
its comment on the timing of the first doses of enoxaparin
and fondaparinux in our study. According to the study pro-
tocol, the first dose of enoxaparin was to be given 12±2
hours preoperatively, except that omission of the preopera-
tive injection was recommended if the use of regional anes-
thesia or epidural catheterization was planned. This approach
is in line with the recommendations of health authorities
in Europe. Because in many cases, surgery was performed
soon after admission and the use of regional anesthesia
was planned, only 25.6 percent of patients received this in-
jection. This outcome reflects the usual situation in clinical
practice, in which it is difficult to administer antithrom-
botic agents preoperatively in emergency situations. My
colleagues and I think that this practice did not result in an
underestimation of the prophylactic effect of enoxaparin.
Furthermore, in one study, treatment with enoxaparin
(40 mg) was initiated preoperatively in 78.1 percent of pa-
tients who were undergoing elective hip surgery, and this
approach was significantly less effective in preventing deep-










 A post hoc logistic-regression analysis of all
phase 3 studies involving patients who first received fonda-
parinux between three and nine hours after orthopedic
surgery showed that there was no significant relation be-





hypothesis that administering low-molecular-weight hepa-
rins close to the time of surgery may increase efficacy has not
been tested in a direct comparison.
Dr. Marlovits suggests that the superior efficacy of fonda-
parinux may reflect a disparity between the number of fon-
daparinux and enoxaparin injections. This is unlikely be-
cause a median of 7 injections of fondaparinux (range, 1 to
11) and of enoxaparin (range, 2 to 10) were administered
up to the time of the qualifying examination for venous
thromboembolism. Furthermore, in a companion study of




 30 mg of enox-
aparin administered twice daily was significantly less effective
in preventing deep-vein thrombosis than was fondaparinux
administered in the same dose regimen that we used.
We believe that factors other than the timing of the ini-
tial dose contributed to the superior efficacy of fonda-
parinux, such as the ability of this agent to inhibit activat-
ed factor X selectively and the rapid onset of action and
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To the Editor: 
 
Priestley cites a study by Hull et al. to bol-
ster his argument that there is no difference between pre-
operative and postoperative administration of dalteparin in
terms of the prevention of venous thromboembolism after




 reported an incidence of
venous thromboembolism of 19.7 percent, which was vir-
tually identical to the rate of 19.1 percent reported by Eriks-
son et al. in the enoxaparin group in their trial and con-
siderably higher than the incidence of 8.3 percent reported




 Several earlier studies of pre-
operatively administered low-molecular-weight heparins have
reported rates of venous thromboembolism similar to that
associated with fondaparinux therapy, but the preoperative
administration of these drugs is contraindicated in patients
who receive regional anesthesia.
I share Priestley’s concern about the pharmacologic
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profile of fondaparinux, especially since the problems with
low-molecular-weight heparins became apparent only after
the drugs had been on the market for several years. I agree
that the precautions for the use of fondaparinux should be
similar to those for the use of low-molecular-weight hepa-
rins. However, I think that the current data support strong
consideration of the use of fondaparinux as prophylaxis
against venous thromboembolism in high-risk patients, es-
pecially those who receive regional anesthesia, since such
patients cannot receive low-molecular-weight heparins pre-
operatively.
Scacewater raises a legitimate question about the inter-
changeability of low-molecular-weight heparins in the treat-
ment of venous thromboembolism. These drugs have clear
differences in their pharmacologic profiles. It is not clear,
however, that these differences result in clinically significant
differences in efficacy. All the studies conducted to date
have compared low-molecular-weight heparin with unfrac-
tionated heparin, and they have shown that dalteparin,
enoxaparin, and tinzaparin, given in appropriate anticoag-
ulant doses, are equivalent to unfractionated heparin in terms
of both safety and efficacy. Although a head-to-head trial
of the low-molecular-weight heparins would be ideal, from
the data available it follows that these agents are equivalent
in the treatment of venous thromboembolism and that the
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Estrogen-Replacement Therapy after Ischemic 
Stroke
 
To the Editor: 
 





estrogen-replacement therapy does not reduce the risk of
stroke in women with a history of cerebrovascular disease.
The fact that the women in this study were treated with es-
trogen alone, without a progestin (“unopposed estrogen”),
arouses concern. The mitogenic effect of unopposed es-





 In 1995, a randomized clinical trial, the Post-
menopausal Estrogen/Progestin Interventions (PEPI) tri-
al, verified the hazards of the use of unopposed estrogen





 On the basis of these and other emerging data, in
1994 the Women’s Health Initiative (in which two of us
are coinvestigators) stopped randomly assigning women
with an intact uterus to receive estrogen alone and subse-
quently randomly assigned only women who had under-
gone a hysterectomy to that intervention.
In the study by Viscoli et al., the use of annual endome-
trial biopsies to screen the endometrium may have mini-





ly cancers may have been detected through surveillance.
But this strategy is clearly suboptimal, since it entails the
promotion of abnormal endometrial growth on the basis
of the rationale that any resulting cancers will be surgically
removed.
Given the results of the PEPI trial and the change in
protocol by the Women’s Health Initiative (from 1995 to
1998), we wonder how Viscoli et al. weighed the known
risks of unopposed estrogen against the unknown benefits
of secondary stroke prevention. Their continued use of un-
opposed estrogen is particularly puzzling because they
could have adopted the strategy of the Women’s Health Ini-
tiative and confined the use of unopposed estrogen to wom-
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The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/
progestin regimens on heart disease risk factors in postmenopausal women: 
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To the Editor: 
 
The goal of our study was to test the ef-
fectiveness of estrogen for the prevention of death and re-
current stroke in women with cerebrovascular disease. Sev-
eral lines of evidence supported the study of unopposed
estrogen in this setting. First, the extensive epidemiologic
evidence in support of the vascular protective effects of es-
trogen involves almost exclusively studies in which estro-










 Therefore, we designed the study to
identify the hormonal regimen with the greatest likelihood
of protecting women against recurrent cerebrovascular dis-
ease. Given the negative results of the study, if we had tested
combined estrogen–progestin therapy, we would have been
unable to determine whether the negative results were due
to the ineffectiveness of estrogen or to the adverse effect
of the progestogen. Indeed, one of the proposed explana-
tions for the results of the Heart and Estrogen/Progestin
Replacement Study is that the increased early risk of car-
diovascular events may have been caused by the medroxy-




It was also unclear whether the effects of estrogen on
the endometrium in the PEPI trial could be generalized to
women in our study, whose average age was 71 years (as
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Because the uterus is typically atrophic in elderly women,
it was uncertain whether estrogen therapy alone would be
associated with similar risks in this population.
To ensure the participants’ safety, all women with a
uterus were prescribed medroxyprogesterone once a year,
so that we could detect early hyperplastic changes in the
endometrium that could be treated effectively; were eval-
uated thoroughly for any episode of unscheduled bleed-
ing; and underwent ultrasonography or endometrial biopsy
at the end of their participation in the study. The average
duration of estrogen exposure in the trial was three years —
an interval we consider to be relatively short. Only two cas-
es of uterine cancer were detected, both within six months
after randomization, suggesting that estrogen-replacement
therapy unmasked preexisting cancers. No other cases of
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Trial. JAMA 1995;273:199-208.
 
Recognition and Management of Anthrax
 
To the Editor: 
 





 states that “incision or débridement of
such early [cutaneous] lesions should be avoided, since this
may increase the possibility of bacteremia.” We believe that
this prohibition does not apply to diagnostic skin biopsies.
Eight of 12 patients in whom cutaneous anthrax has
been diagnosed since early October have undergone biop-
sies of their skin lesions. Immunohistochemical staining for










 All other serologic studies or skin tests were less
sensitive. For example, in the initial patient with cutaneous
anthrax, culture and Gram’s staining of serous fluid from
skin lesions were negative, but immunohistochemical analy-




 If a patient has al-





will be thwarted, but an immunohisto-
chemical analysis of the skin will remain positive.
When we were preparing an algorithm for evaluating
patients with suspected cutaneous anthrax for the Bioter-
rorism Taskforce of the American Academy of Dermatol-
ogy (available at http://www.eblue.org/anthrax), we tried
to trace the origin of the oft-repeated caution regarding
surgical manipulation. We were unable to find a primary ref-
erence or further substantiation. The remark may predate
the antibiotic era. Without antibiotics, bacteremia might
change the course of (usually benign) cutaneous disease into
(usually lethal) systemic disease. Today, with the simulta-
neous administration of antibiotics, the danger is minimal.
Our algorithm, which is consistent with the one published





ommends the biopsy of suspicious lesions.
(The opinions expressed in this letter are those of the
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Swartz MN. Recognition and management of anthrax — an update.




Update: investigation of anthrax associated with intentional exposure 
and interim public health guidelines, October 2001. MMWR Morb Mortal 





Update: investigation of bioterrorism-related anthrax and interim guide-
lines for exposure management and antimicrobial therapy, October 2001. 





Update: investigation of bioterrorism-related anthrax and interim 
guidelines for clinical evaluation of person with possible anthrax. MMWR 





Update: investigation of bioterrorism-related anthrax and adverse events 
from antimicrobial prophylaxis. MMWR Morb Mortal Wkly Rep 2001;50:
973-6. (Also available at http://www.cdc.gov/mmwr/preview/
mmwrhtml/mm5044a1.htm.)
 
To the Editor: Dr. Swartz recommends the use of contact
precautions for patients with draining cutaneous lesions
and standard precautions for all others hospitalized with
anthrax infection. However, during the recent bioterror-
ism-related anthrax events, more than 20 cases of cutane-
ous and inhalational anthrax were caused by contact with
letters containing spores, suggesting that the risk of ac-
quiring the disease from fomites might be higher than was
previously realized.1-3 Spores such as those found in the
Hart Senate Office Building may have been weaponized to
permit them to spread more easily. We have no data on the
risks of person-to-person transmission or reaerosolization
of these spores. This information will be critical for defin-
ing guidelines for infection control.
Decontamination of skin and clothing is recommended
after a release of anthrax in order to reduce the risk of cu-
taneous disease, but such decontamination may present lo-
gistical difficulties.1,4 If victims are not decontaminated be-
fore they go to the hospital, health care workers may be
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exposed to anthrax spores and may thus be at risk for cu-
taneous, and possibly even inhalational, infection.
The recent cases of bioterrorism-related anthrax are forc-
ing us to rethink the likelihood of patient-to-patient trans-
mission and secondary aerosolization. To prevent the spread
of anthrax spores to hospital workers, it may be prudent
to use contact precautions for all patients who have been
exposed to anthrax until they have been decontaminated.
Isolation to prevent the spread of airborne spores should
also be considered until more data on secondary aerosoliza-
tion are available. This more stringent standard of care will
help protect all hospital personnel.
VINCENT LO RE III, M.D.
NEIL O. FISHMAN, M.D.
Hospital of the University of Pennsylvania
Philadelphia, PA 19104
vincentl@mail.med.upenn.edu
1. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological 
weapon: medical and public health management. JAMA 1999;281:1735-
45.
2. Pile JC, Malone JD, Eitzen EM, et al. Anthrax as a potential biological 
warfare agent. Arch Intern Med 1998;158:429-34.
3. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax 
outbreak of 1979. Science 1994;266:1202-8.
4. Bioterrorism alleging use of anthrax and interim guidelines for manage-
ment — United States, 1998. MMWR Morb Mortal Wkly Rep 1999;48:
69-74.
To the Editor: The terminal phase of anthrax results from
toxemia. Once toxemia has reached a certain level, antibi-
otic therapy is no longer effective, since it does not lower
the blood toxin level. The blood itself becomes toxic, in
that sterile serum is lethal when injected into animals. Since
pulmonary anthrax is usually well along on its pathologic
course at the time of presentation, it is unlikely that anti-
biotic therapy alone can effect a cure.
When a patient presents with a blood toxin level ap-
proaching the lethal level, should complete blood replace-
ment be used to lower the blood toxin level to a sublethal
level so that the antibiotics can have a chance to work? The
infused blood could contain an appropriate level of antibi-
otic, although there is still a possibility that the lysis of bac-
teria might increase the toxin level. Blood replacement might
be used to buy time by lowering toxin levels to a point at
which antibiotic therapy could be effective.
PAT KING, B.S.
219 Glade
Hot Springs, AR 71901
patking13@earthlink.net
To the Editor: Dr. Swartz states that person-to-person
transmission of anthrax has not been reported. We are aware
of several published reports describing person-to-person
transmission of cutaneous anthrax, including anecdotal re-
ports,1,2 a case report,3 and an investigation of an out-
break.4 Two of these reports described nosocomial acquisi-
tion by a health care worker — in one case, a nursing orderly
who contracted anthrax while dressing the lesion of a pa-
tient,1 and in the other, an “unqualified general worker”
who contracted anthrax after handling the soiled dressing
of a patient with a new case of cutaneous anthrax.2 A case
series from Mexico included a case of skin infection on a
baby’s elbow that was thought to have been acquired from
an infection on the mother’s finger.3 Finally, an investigation
of an anthrax outbreak in India included the report of two
cutaneous cases that occurred 40 and 60 days after the
death of the first infected animal.4 The authors concluded
that these were probably due to human-to-human transmis-
sion, since in all other cases, cutaneous lesions appeared 1 to
13 days after the patient had handled a sick animal or eaten
contaminated meat.
The standard precaution of using gloves to touch non-
intact skin should prevent the transmission of cutaneous
anthrax to health care workers. For added protection, we
have recommended that contact precautions be used with
patients with cutaneous anthrax.5 As Dr. Swartz notes, po-
tentially contaminated bandage material should be handled
as regulated waste. We are unaware of any reports of per-
son-to-person transmission of inhalational anthrax.
DAVID J. WEBER, M.D., M.P.H.
WILLIAM A. RUTALA, PH.D., M.P.H.
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-7033
dweber@unch.unc.edu
1. Turnbull PCB. Anthrax. In: Palmer SR, Soulsby L, Simpson DIH, eds. 
Zoonoses: biology, clinical practice, and public health control. Oxford, 
England: Oxford University Press, 1998:3-16.
2. Pugh AO, Davies JCA. Human anthrax in Zimbabwe. Salisbury Med 
Bull Suppl 1990;68:32-3.
3. Nunez JV. Pustula maligna. Dermatologia Revista Mexicana 1960;4:
4-19.
4. Sekhar PC, Singh RS, Sridhar MS, Bhaskar CJ, Rao YS. Outbreak of 
human anthrax in Ramabhadrapuram village of Chittoor district in Andhra 
Pradesh. Indian J Med Res 1990;91:448-52.
5. Weber DJ, Rutala WA. Risks and prevention of nosocomial transmission 
of rare zoonotic diseases. Clin Infect Dis 2001;32:446-56.
Dr. Swartz replies:
To the Editor: Drs. McGovern and Norton question the
basis of the recommendation that débridement of cutane-
ous lesions of anthrax be avoided and point out that eight
patients with such lesions in the recent outbreak under-
went biopsy uneventfully. The recommendation for avoid-
ance of incision and débridement dates back to the era be-
fore antibiotics. The prominent localized perilesional edema
has sometimes misleadingly suggested abscess formation
and led to attempts at incision and drainage, which may
have contributed to the bacteremia that occasionally com-
plicates cutaneous anthrax. Performing a biopsy of the
skin while simultaneously administering antibiotics, as was
done during the recent outbreak, would entail minimal
risk while allowing prompt diagnosis.
Drs. Lo Re and Fishman express concern about person-
to-person transmission or reaerosolization of weaponized
B. anthracis spores after a bioterrorism-related release. They
are concerned that if victims are not decontaminated be-
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV OF NC/ACQ SRVCS on June 9, 2020. For personal use only. No other uses without permission. 
 Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
CORRESPONDENCE
N Engl J Med, Vol. 346, No. 12 · March 21, 2002 · www.nejm.org · 945
fore being hospitalized, they may serve as a source of in-
fection for health care workers. They advocate the use of
contact precautions for patients who have been exposed to
anthrax. Certainly, prompt decontamination of the environ-
ment, including skin and clothing, after a known release
of B. anthracis spores is indicated. However, persons with
cutaneous or inhalational anthrax would present some days
after exposure and are infected with the vegetative forms
of the organism, which are much less likely to be a source
of person-to-person spread. Nonetheless, if heavy contam-
ination of skin and clothing has occurred and initial de-
contamination has not been performed, reaerosolization
and person-to-person spread are possible. In the recent out-
break, the time of exposure was known only in retrospect,
which precluded prompt decontamination. Nonetheless,
secondary cases among family contacts were not reported.
Ms. King raises the question of exchange transfusion in
the late stage of inhalational anthrax as a means of preventing
toxin-related death before antimicrobial action can take ef-
fect. The amount of tissue-bound toxin that would be
present at this point and the likely hemodynamic compro-
mise would probably limit the likelihood of success. A potent
antitoxic antiserum or the recently developed inhibitor of an-
thrax toxin that binds to the heptameric protective antigen
(PA) and blocks its interaction with edema factor (EF) and
lethal factor (LF) may be more fruitful future approaches.1
Drs. Weber and Rutala refer to a few anecdotal reports
suggesting person-to-person spread of cutaneous anthrax.
Several of these reports were from areas (Africa and India)
where the disease is endemic and where infection may have
spread from a more conventional source. More convincing
is the case in Mexico of skin infection on a baby’s elbow
that could have been acquired from an infection on the
mother’s finger. However, the rarity of these reports should
be emphasized. Drs. Weber and Rutala agree that the use
of standard precautions (including the use of gloves for
contact with nonintact skin) should prevent the transmis-
sion of cutaneous anthrax to health care workers, but they
would take the added step of implementing contact pre-
cautions for all patients with cutaneous anthrax.




1. Mourez M, Kane RS, Mogridge J, et al. Designing a polyvalent inhibi-
tor of anthrax toxin. Nat Biotechnol 2001;19:958-61.
Cutaneous Anthrax Infection
To the Editor: Like many other clinicians, we were dis-
heartened by the report of the diagnosis of cutaneous an-
thrax in a seven-month-old child (Nov. 29 issue).1 How-
ever, what we found most distressing about this and other
cases was that the initial diagnosis was envenomation by the
brown recluse spider, Loxosceles reclusa. Although enveno-
mation by this spider produces a necrotic lesion that may be
mistaken for cutaneous anthrax, there are some critical dif-
ferences that can help to guide future evaluations.
Loxosceles spiders prefer warm temperatures, and they
are not native to the northern half of the United States.2 In
fact, no spider causing necrotic lesions is known to live in
New York City. Furthermore, as the spider’s name implies,
these spiders are most commonly found hidden in wood-
piles or barns — areas that are not typically visited by small
children, as evidenced by the fact that few case series have
included small children.3,4
Examination of the patient with a loxosceles bite generally
reveals a painful blister, which may develop a dark purple
coloration, with subsequent central necrosis of the lesion.3
Unlike such bites, the lesions associated with cutaneous
anthrax are often painless. The substantial edema and re-
gional adenopathy that are characteristic of cutaneous an-
thrax are generally absent in patients with loxosceles en-
venomation.5 Thus, despite some superficial similarity, a
painless, edematous, necrotic lesion with local adenopathy
in a person in the northeastern United States, especially in
the colder months, is not likely to represent necrotic
arachnidism.
LEWIS S. NELSON, M.D.
New York City Poison Control Center
New York, NY 10016
lnelson@pol.net
ROBERT HANNER, PH.D.
American Museum of Natural History
New York, NY 10024
ROBERT S. HOFFMAN, M.D.
New York City Poison Control Center
New York, NY 10016
1. Roche KJ, Chang MW, Lazarus H. Cutaneous anthrax infection.
N Engl J Med 2001;345:1611.
2. Necrotic arachnidism — Pacific Northwest, 1988–1996. MMWR Morb 
Mortal Wkly Rep 1996;45:433-6.
3. Wright SW, Wrenn KD, Murray L, Seger D. Clinical presentation and 
outcome of brown recluse spider bite. Ann Emerg Med 1997;30:28-32.
4. Ingber A, Trattner A, Cleper R, Sandbank M. Morbidity of brown re-
cluse spider bites: clinical picture, treatment and prognosis. Acta Derm Ve-
nereol 1991;71:337-40.
5. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J 
Med 1999;341:815-26.
The authors reply:
To the Editor: The purpose of this Image in Clinical
Medicine was to present an example of early cutaneous an-
thrax, since most reports show older, necrotic lesions. Be-
cause of space limitations, we did not discuss the differen-
tial diagnosis or other important issues involved in this
complicated case.
We agree that the painless nature of the lesion was not
typical of the bite of a brown recluse spider and that ne-
crotic arachnidism in an infant in Manhattan is very un-
likely. However, we could not rule out this possibility. Al-
though loxosceles spiders are most highly concentrated in
the south central United States, loxosceles species have been
identified in virtually every state in the continental United
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States,1 and according to one spider expert, a “cousin” of
the brown recluse spider, L. refuscens, had recently been
sighted in the New York area. The family’s car had recently
been in regions inhabited by loxosceles species, and we
postulated that a spider might have hidden in the infant’s
stroller or in the family’s belongings. Although loxosceles
bites are most common in the summer, a second peak can
occur when victims unpack boxes and resume wearing
stored winter clothing in which the spider may be hiding.2
Furthermore, life-threatening hemolysis, thrombocytope-
nia, disseminated intravascular coagulation, hyponatremia,
and acute renal failure developed in this infant, and all of
these complications have been well described in patients
with loxosceles envenomation.1,2 A putative brown recluse
spider bite1,2 was the initial working diagnosis; since there
is no specific antidote for such bites, the patient received
antibiotics, corticosteroids, and supportive care, which was
the appropriate therapy, even in retrospect.
At the time, anthrax in a seven-month-old child in Man-
hattan seemed nearly impossible. In fact, between 1984 and
2000, only five cases of cutaneous anthrax were reported in
this country, and none of these occurred in children.3,4
During this child’s hospitalization, the first case of cutane-
ous anthrax in New York City was reported. The correct di-
agnosis in the child was then rapidly confirmed. The con-
stellation of systemic complications is highly unusual in a
patient of any age with cutaneous anthrax, and such com-
plications have never been reported in a child, even in coun-
tries where anthrax is endemic.5 Fortunately, the infection
responded well to therapy, and the child recovered fully.
We are certainly wiser now than we were before Sep-
tember 11, 2001. A full case report of this infant’s illness
has been published, including serial photographs of the
evolving lesion.5 The early recognition of anthrax is crucial
in patients of all ages.
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Sudden Death Due to Cardiac Arrhythmias
To the Editor: Spironolactone should be added to Table 2
of the article by Huikuri et al. (Nov. 15 issue)1 as an inter-
vention that may prevent sudden death from cardiac causes.
In the Randomized Aldactone Evaluation Study,2 patients
with New York Heart Association class III or IV conges-
tive heart failure who were randomly assigned to receive
daily spironolactone had a lower risk of sudden death than
patients who were randomly assigned to receive placebo
(relative risk, 0.71; 95 percent confidence interval, 0.54 to
0.95; P=0.02). Possible mechanisms of this protective ef-
fect include potentiation of diuretic-induced hypokalemia
as well as neurohormonal interactions.2
DAVID BERLIN, M.D.
New York Presbyterian Hospital–Weill Cornell Medical Center
New York, NY 10021
berlind-d@mailcity.com
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2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on 
morbidity and mortality in patients with severe heart failure. N Engl J Med 
1999;341:709-17.
To the Editor: The interesting review article on sudden
death due to cardiac arrhythmias by Huikuri and colleagues
did not comment on n¡3 fatty acids as useful agents for the
primary prevention of sudden death. These naturally occur-
ring compounds are underused in this country and could
potentially save thousands of lives each year.
Large, randomized prospective trials have shown that
fish1 or fish-oil capsules,2 which provide approximately 1 g of
n¡3 fatty acids daily, can reduce the risk of sudden death by
50 percent in persons who have had a myocardial infarction.
These fatty acids stabilize the electrical activity of cardiac
myocytes by inhibiting membrane ion channels and pro-
longing the relative refractory period.3 They also exert an
antiarrhythmic action by increasing heart-rate variability.4
In addition to beta-blockers, n¡3 fatty acids should be
considered to be accepted therapeutic agents for prevent-
ing sudden death in persons who have had a myocardial
infarction.
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The authors reply:
To the Editor: Dr. Berlin suggests that spironolactone
and Dr. Goldstein proposes that n¡3 fatty acids should be
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included on the list of accepted therapeutic agents for pre-
venting sudden death from cardiac causes. Indeed, two ran-
domized trials have shown that fish1 or fish-oil capsules2 can
reduce the risk of the combined end point of death, my-
ocardial infarction, and stroke among patients with a prior
myocardial infarction. In the Randomized Aldactone Eval-
uation Study,3 spironolactone lowered the risk of death
among patients with heart failure. Subanalyses of the results
of these trials have also suggested that both n¡3 fatty acids
and spironolactone may reduce the risk of sudden death.
Despite these promising results, there are some short-
comings in the designs of these trials that prevent the gen-
eralization of the concept that these agents have a definite
role in the primary prevention of sudden death from ar-
rhythmia. First, none of these trials included sudden
death from cardiac causes as a primary end point, and
therefore, the studies were not powered accordingly. Sec-
ond, there were no prespecified definitions of sudden
death from cardiac causes in any of these trials, and only
one end-point committee defined the mode of death. In
fact, a recent beta-blocker study4 was the first drug trial
that paid specific attention to the definition of sudden
death from cardiac causes. On the basis of the results of
that trial and concordant information from a subanalysis
of several other beta-blocker trials, we concluded that
only in the case of beta-blocking drugs was there suffi-
cient evidence to warrant their inclusion as a recommend-
ed treatment for the primary prevention of sudden death
from cardiac causes.
Definitive evidence from prospective trials should be a
requirement before any therapeutic strategy is widely rec-
ommended and accepted. Any new preventive strategies
that can decrease the worldwide problem of sudden death
from cardiac causes will be welcomed, but the overall and
individual effects5 must first be proved by means of care-
fully planned and executed clinical trials.





ROBERT J. MYERBURG, M.D.
University of Miami School of Medicine
Miami, FL 33101
1. Burr ML, Gilbert JF, Holliday RM, et al. Effects of changes in fat, fish, 
and fiber intakes on death and myocardial reinfarction: Diet and Reinfarc-
tion Trial (DART). Lancet 1989;334:757-61.
2. GISSI-Prevenzione Investigators. Dietary supplementation with n¡3 
polyunsaturated fatty acids and vitamin E after myocardial infarction: 
results of the GISSI-Prevenzione Trial. Lancet 1999;354:447-55. [Erra-
tum, Lancet 2001;357:642.]
3. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on 
morbidity and mortality in patients with severe heart failure. N Engl J Med 
1999;341:709-17.
4. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol 
CR/XL Randomised Intervention Trial in Congestive Heart Failure 
(MERIT-HF). Lancet 1999;353:2001-7.
5. Myerburg RJ, Mitrani R, Interian A Jr, Castellanos A. Interpretation of 
outcomes of antiarrhythmic clinical trials: design features and population 
impact. Circulation 1998;97:1514-21.
Red Pepper and Functional Dyspepsia
To the Editor: Functional dyspepsia is a common and
distressing chronic digestive disorder of unknown cause.1,2
We examined the effect of treatment of functional dyspepsia
with capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide), a
component of red-pepper (Capsicum annum) powder. Cap-
saicin selectively impairs the activity of nociceptive C fibers
carrying pain sensations to the central nervous system3
and has been shown to relieve pain of cutaneous and mu-
cosal origin.4
After the exclusion of patients with gastroesophageal re-
flux and irritable bowel syndrome, we monitored 30 patients
with functional dyspepsia2 for two weeks while they were
receiving no medications. Fifteen patients were randomly
assigned in a double-blind manner to receive 2.5 g of red-
pepper powder a day (contained in capsules taken before
each of three meals) for five weeks, and the other 15 were
randomly assigned to receive placebo capsules. The capsa-
icin content was 0.7 mg per gram of red-pepper powder,
as determined by means of high-performance liquid chro-
matography. A diary sheet was given to each patient to
record daily symptom scores. The symptom scores ob-
tained in the red-pepper group during the entire treatment
period were compared with those obtained in the placebo
Figure 1. Mean (±SD) Scores for Overall and Individual Symp-
toms during the Entire Treatment Period with Red Pepper or
Placebo.
Higher scores indicate more severe symptoms. Asterisks indi-
cate a significant difference (P<0.05) between the groups. The
difference between groups in the early-satiety score was at the
borderline of significance (P<0.06); the results of analyses of oth-
er symptoms considered in the study, such as epigastric burning,
bloating, and burping, were not included in the figure, because
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group, and the mean weekly scores in both groups were
plotted against time and compared between groups and
with the corresponding base-line value obtained the week
before treatment began. Parametric tests (analysis of vari-
ance for repeated measurements and Student’s t-test for
paired data) and a nonparametric test (the Mann–Whitney
U test) were used as appropriate.
Two of the 15 patients in the red-pepper group discon-
tinued the trial because of epigastric pain, and 1 patient in
the placebo group stopped treatment for other reasons (P=
1.00 by Fisher’s exact test). The overall symptom scores as
well as the scores for epigastric pain, epigastric fullness, and
nausea during the entire treatment period were significantly
lower in the red-pepper group than in the placebo group
(Fig. 1). The weekly scores in the red-pepper group were
significantly lower than those in the placebo group begin-
ning in the third week of treatment (Table 1) and, in the last
week of treatment, had decreased by a mean of approxi-
mately 60 percent, whereas those in the placebo group
had decreased by approximately 30 percent. The adminis-
tration of red pepper was more effective than placebo in
decreasing the intensity of dyspeptic symptoms, probably
through a capsaicin-induced desensitization of gastric no-
ciceptive C fibers. Although larger trials with standardized
materials are needed, capsaicin could represent a potential
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*Plus–minus values are means ±SD. Higher scores indicate more severe symptoms. Both the overall and individual
symptom scores of patients treated with red pepper were significantly lower than base-line values from the second week
onward, whereas symptom scores in the placebo group decreased significantly beginning in the first week. However, be-
ginning in the third week all individual and global scores in the red-pepper group were significantly lower than those in
the placebo group.
†P<0.05 for the comparison with base-line values.
‡P<0.05 for the comparison with the placebo group.
TABLE 1. BASE-LINE AND WEEKLY SCORES FOR OVERALL AND INDIVIDUAL SYMPTOMS 
IN THE RED-PEPPER GROUP AND THE PLACEBO GROUP.*
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